Bio-Techne CorpNasdaq: TECH
Health Care · Life Sciences Tools & Services
$57.98
+5.42%
Vol: 2.2M
Research Digest
Friday, June 19, 2026
Bio-Techne shares rise 30% in a month after Refeyn bispecific antibody collaboration; analysts hold mixed views amid China and federal funding headwinds.
Bio-Techne announced a collaboration with Refeyn, providing an integrated four-hour workflow linking charge heterogeneity, molecular weight, and aggregation analysis for bispecific antibodies and biosimilars at single-molecule resolution, which drove a 29.7% share price gain over the past month. As of June 17, 2026, the analyst consensus across 10 firms is Buy. Piper Sandler assigned a Neutral rating on June 11 while TD Cowen maintained a Buy on the same date. Key headwinds include muted revenue growth from weak conditions in China, concerns in the pharmaceutical and academic end markets, and uncertainty around federal research funding and drug pricing reform. The stock is considered fully valued at current levels after the sharp rally, and any deterioration in U.S. NIH funding or continued China weakness could pressure results in coming quarters.
Previous Market Intelligence
13 daysJun 18No significant overnight updatesNeutral▶
No material news in the last 48 hours.
Jun 17Bio-Techne shares rose about 4% after activist Ananym Capital Management disclosed a significant stake and pushed for a strategic review.Positive▶
On June 15, 2026, Bio-Techne (TECH) shares climbed roughly 4% after activist investor Ananym Capital Management acquired a significant stake and began pushing for a strategic review of the life-science tools company. The activist pressure lands amid soft fundamentals: Bio-Techne reported a 2% revenue decline in its fiscal third quarter with adjusted operating margin of 34.2% (down 70 basis points), and high-single-digit declines in revenue from biotech customers. The two-segment company derives about 75% of revenue from protein sciences and 25% from diagnostics and genomics. Activist involvement raises the prospect of cost cuts, portfolio changes, or a potential break-up that could unlock value. The bear case is that weak end-market demand and stretched valuation persist regardless of activist action, and strategic reviews carry execution and timing risk. Analyst views remain mixed, with a Moderate Buy consensus and price targets around $68.
Jun 16Bio-Techne shares rose ~4% after activist Ananym Capital disclosed a stake and pushed for a strategic review, including a possible sale.Positive▶
Bio-Techne (TECH) shares gained about 4% on June 15, 2026 after activist investor Ananym Capital Management disclosed a significant stake and began pushing for a strategic review, raising the prospect that the company could explore a sale. Ananym argues the current independent structure may not be maximizing shareholder value, putting governance and capital allocation under investor scrutiny. The pressure comes after a soft fiscal quarter: Bio-Techne reported May 6, 2026 EPS of $0.53, narrowly missing the $0.534 consensus, amid concerns over weak revenue growth and a high valuation. The company operates Protein Sciences (~75% of revenue) and Diagnostics/Spatial Biology (~25%), and is launching new neurology assays and antibody-characterization workflows. The bear case: an activist campaign offers no guaranteed outcome, and sluggish organic growth plus a rich multiple could cap upside if a sale or strategic shift fails to materialize.
Jun 15No significant overnight updatesNeutral▶
No material news in the last 48 hours.
Jun 14No significant overnight updatesNeutral▶
No material news in the last 48 hours.
May 21No significant overnight updatesNeutral▶
No material news in the last 48 hours.
May 20Bio-Techne shares fell 16% after Q3 FY26 organic revenue declined 2% with biotech customer weakness and Evercore ISI cutting price target.Negative▶
Bio-Techne reported Q3 FY2026 results on May 6, 2026, with reported and organic revenue declining 2% to $311.4M, impacted by prior-year GMP fast-track orders and large Commercial Supply shipment timing. GAAP EPS rose to $0.32 from $0.14, while adjusted EPS was $0.53 (down from $0.56). Large pharma delivered a sixth consecutive quarter of double-digit growth, but emerging biotech spending continued to lag with high-single-digit declines. Shares sold off 16% on concerns over biotech demand and AI's impact on growth. The board declared a $0.08 quarterly dividend. Evercore ISI lowered its price target to $50 from $54 on May 7. CEO Kim Kelderman presented at the BofA Global Healthcare Conference on May 12.
May 19Bio-Techne reported Q3 fiscal 2026 revenue of $311.4M (-2%) and adjusted EPS of $0.53, sending shares down 16% on May 6, 2026.Negative▶
Bio-Techne reported Q3 fiscal 2026 revenue of $311.4M, down 2% organic and reported, missing estimates by ~$12M, with adjusted EPS of $0.53 (down from $0.56) also missing by $0.02. GAAP EPS rose to $0.32 from $0.14, but shares sold off 16% on the report as biotech customer revenue declined in high single digits and adjusted operating margin compressed 70bps to 34.2%. Large pharma posted its sixth straight quarter of double-digit growth, Spatial Biology grew mid-teens, and GMP proteins (ex-fast track) grew nearly 50%, partially offsetting emerging biotech weakness. The Board declared a $0.08 quarterly dividend. Evercore ISI cut its PT to $50 from $54 on May 7, while RBC Capital resumed coverage with an Outperform rating on May 14. CEO Kim Kelderman presented at the Bank of America 2026 Global Healthcare Conference on May 12.
May 18No significant overnight updatesNeutral▶
No material news in the last 48 hours.
May 15Bio-Techne shares dropped 16% after Q3 FY26 revenue fell 2% to $311M; six analysts slashed targetsNegative▶
Bio-Techne reported Q3 fiscal 2026 net sales of $311.4M, down 2% YoY with organic revenue down 2%. Adjusted EPS was $0.53 versus $0.56 year-ago, and adjusted operating margin contracted 70 bps to 34.2%. Shares sold off 16% from the prior close as biotech-customer revenue declined high single digits. Six firms cut price targets on May 7 - Baird ($70 to $49), Stifel ($65 to $50), Wells Fargo ($76 to $62), Deutsche Bank ($75 to $66), Citi ($80 to $70), and Evercore ISI ($54 to $50). Bright spots included strong large pharma, mid-teens Spatial Biology growth, and near-50% GMP protein growth ex fast-track orders. Director Amy Herr sold 6,636 shares for $320K on May 12.
May 14Bio-Techne CEO Kim Kelderman pitched Q3 turnaround story at BofA Healthcare Conference on May 12 after revenue declined 2% YoY.Mixed▶
CEO Kim Kelderman presented at the Bank of America Securities 2026 Global Healthcare Conference on May 12, 2026 at 9:20 a.m. PDT. The fireside chat follows Bio-Techne's Q3 FY2026 results (May 6) where reported and organic revenue declined 2% to $311.4M — hurt by prior-year GMP fast-track comps and timing of Commercial Supply shipments — while GAAP EPS rose to $0.32 from $0.14 and adjusted EPS slipped to $0.53 from $0.56 (missing consensus by $0.02). The board declared an $0.08/share quarterly dividend. Wells Fargo cut its PT to $62 from $76 (Overweight) on May 7; Deutsche Bank, Baird, and Stifel also trimmed targets. Despite the revenue decline, shares climbed 5.9% post-earnings on improved profitability. TradeLink Capital LLC disclosed a new position on May 12.
May 13Bio-Techne reported Q3 FY26 revenue down 2% to $311.4M on May 6 with mixed segment performance, declared an $0.08 dividend, and CEO presented at BofA Healthcare Conference on May 12.Mixed▶
On May 6, 2026, Bio-Techne reported Q3 FY26 (quarter ending March 31, 2026) revenue of $311.4M, down 2% reported and organic, weighed by prior-year GMP fast-track orders and timing of large commercial supply shipments. Large pharma delivered the sixth consecutive quarter of double-digit growth, offset by continued lag in emerging biotech spending; U.S. academic markets stabilized with low-single-digit growth. Growth vectors included mid-single-digit growth in Proteomic Analysis instruments, mid-teens in Spatial Biology, and nearly 50% growth in GMP proteins excluding fast-track customers. The Board declared a $0.08 per share dividend for the quarter. CEO Kim Kelderman presented at the BofA Securities 2026 Global Healthcare Conference on May 12. Risk: emerging biotech funding remains weak and academic NIH-tied spending is choppy, limiting near-term top-line acceleration.
May 12Bio-Techne CEO Kim Kelderman presents at the BofA Global Healthcare Conference on May 12 at 9:20 a.m. PDT following a Q3 FY26 revenue miss and a Wells Fargo PT cut to $62 from $76.Mixed▶
Bio-Techne CEO Kim Kelderman is scheduled to present at the BofA Securities 2026 Global Healthcare Conference today, May 12, at 9:20 a.m. PDT, the first major investor event since the May 6 Q3 FY26 print where revenue fell 2% YoY to $311.4M and adjusted EPS of $0.53 missed the $0.55 consensus. The presentation matters because large-pharma demand grew double digits for the sixth straight quarter while emerging-biotech spending remained weak, and investors are looking for incremental commentary on the pace of recovery. Bear case: Wells Fargo cut its price target to $62 from $76 on May 7 while keeping Overweight, signaling that even bulls now see a slower path to reacceleration as the biotech funding overhang persists.
Key Fundamentals
RSI (14-Day)
52-Week Range
Moving Averages
Price above both MAs — bullish structure.